Search

Your search keyword '"Solomon, Scott"' showing total 470 results

Search Constraints

Start Over You searched for: Author "Solomon, Scott" Remove constraint Author: "Solomon, Scott" Journal journal of the american college of cardiology Remove constraint Journal: journal of the american college of cardiology
470 results on '"Solomon, Scott"'

Search Results

5. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial

7. Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis

8. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials JACC Review Topic of the Week

10. Kidney Function and Outcomes in Patients Hospitalized With Heart Failure

11. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function

12. Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection Fraction

14. Cardiovascular-Kidney-Metabolic Overlap in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis

16. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction

18. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction

19. Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction

23. Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF

25. Incidence and Outcomes of Pneumonia in Patients With Heart Failure

33. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure

34. Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure

36. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

37. Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory

38. Right Ventricular Function and Coupling to Pulmonary Circulation in Heart Failure with Preserved Ejection Fraction: The PARAGON-HF Trial

39. Virtual Care Team Guided Management of Patients With Heart Failure During Hospitalization

40. MISSENSE GENETIC VARIATION OF ICAM1 AND INCIDENT HEART FAILURE: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS

41. WHY MEASURE NT-PROBNP SERIALLY IN CHRONIC HEART FAILURE? MECHANISTIC ASSOCIATIONS OF NATRIURETIC PEPTIDE SLOPE FOLLOWING INITIATION OF SACUBITRIL/VALSARTAN

42. AFICAMTEN IN PATIENTS WITH SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (REDWOOD-HCM COHORT 4)

43. GEOGRAPHICAL VARIATION IN PATIENT CHARACTERISTICS AND OUTCOMES IN HFPEF

44. THE EFFECT OF DAPAGLIFLOZIN ON INSULIN INITIATION OR INTENSIFICATION IN PATIENTS IN HEART FAILURE AND DIABETES: A POOLED ANALYSIS OF DAPA-HF AND DELIVER

45. PREDICTING STROKE IN HEART FAILURE AND PRESERVED EJECTION FRACTION WITHOUT ATRIAL FIBRILLATION

46. GROWTH DIFFERENTIATION FACTOR-15, CLINICAL OUTCOMES, AND THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION: INSIGHTS FROM THE DAPA-HF TRIAL

48. RED CELL DISTRIBUTION WIDTH IS AN INDEPENDENT PREDICTOR OF OUTCOMES IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: AN ANALYSIS OF THE PARAGON-HF TRIAL

49. CA125 IN PATIENTS WITH HFREF AND THE EFFECT OF DAPAGLIFLOZIN: INSIGHTS FROM DAPA-HF

50. LONG-TERM EFFICACY AND SAFETY OF AFICAMTEN IN PATIENTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

Catalog

Books, media, physical & digital resources